NeoGenomics, Inc.
$2.42B- Market cap
- $2.23B
- Debt
- +$341.86M
- Cash
- −$159.62M
Capital structure 87% equity / 13% debt · EV / Revenue 3.32x
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2026 · Mkt cap
Decision snapshot: NEO stock price at premium vs DBI $17.38 current versus $0.94 implied using P/S multiple.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at DBI's multiple
Implied fair value · at NEO's multiple
Snapshot Sep 4, 4:00 PM ET
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Pricing power
Operating leverage
Multiple premium
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: NEO FY 2025 (ended Dec 31, 2025) · DBI FY 2026 (ended Jan 31, 2026). Fiscal years are not aligned.
Trendline
Ten fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Capital structure 87% equity / 13% debt · EV / Revenue 3.32x
Capital structure 52% equity / 48% debt · EV / Revenue 0.30x · EV / EBITDA 18.40x
NEO carries the larger enterprise value at $2.42B against $862.53M; DBI trades on the lower EV / Revenue multiple (0.30x vs 3.32x).
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
NeoGenomics, Inc. · implied price per share
Latest annual free cash flow must be positive to qualify the filing-backed baseline.
DESIGNER BRANDS INC. · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Debt / equity
Total debt against shareholders' equity
0.41x
1.54x
Net debt / EBITDA
Leverage against operating earnings
-4.48x
8.20x
Cash and equivalents
Liquid reserves on the balance sheet
$159.62M
$50.87M
Total debt
Interest-bearing obligations outstanding
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
LABCORP HOLDINGS INC.
NEO vs LH
QUEST DIAGNOSTICS INC
NEO vs DGX
OPKO HEALTH, INC.
NEO vs OPK
Guardant Health, Inc.
NEO vs GH
Natera, Inc.
NEO vs NTRA
EXACT SCIENCES CORP
NEO vs EXAS
FOOT LOCKER, INC.
NEO vs FL
TJX COMPANIES INC /DE/
NEO vs TJX
Macy's, Inc.
NEO vs M
SHOE CARNIVAL INC
NEO vs SCVL
GENESCO INC
NEO vs GCO
WOLVERINE WORLD WIDE INC /DE/
NEO vs WWW
$341.86M
$434.96M
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.